TRVI - Trevi climbs after positive interim data for Haduvio in mid-stage cough study

The shares of Trevi Therapeutics (NASDAQ:TRVI) have added ~52% in the pre-market Thursday after the clinical-stage biopharmaceutical company announced positive interim results for its investigational therapy Haduvio from a Phase 2 trial involving patients with chronic cough. The CANAL (Cough And NALbuphine) study was designed to evaluate the oral extended-release (ER) formulation of nalbuphine in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough. Based on data from 26 patients, there was a statistical significance in the primary efficacy endpoint indicating a 52% placebo-adjusted reduction in daytime cough events for Haduvio in terms of geometric mean percent change (p<0.0001, conditional power 100%). Haduvio was also found to be well-tolerated in the trial with no new safety signals and a safety profile in line with prior studies. With the analysis indicating a 100% chance of success based on existing data, the company has decided to end screening and the enrollment in the trial.

For further details see:

Trevi climbs after positive interim data for Haduvio in mid-stage cough study